Accès ouvert
2025
article
OpenAlex
Elena Johanna Weigl, Thorsten Walles, Sarah Nietzer, Gudrun Dandekar et autres
Lung cancer is the leading cause for cancer related death worldwide. One treatment option for patients with pulmonary adenocarcinoma is the targeted therapy gefitinib (Iressa®, ZD1839). As with other promising targeted therapies, desired in vivo effects of gefitinib came short to in …
de
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
J. Nieves, Sarah Nietzer, Tobias Weigel, Lisa Bauer et autres
The development of bone metastases poses a clinical challenge for patients with malignancies originating from diverse organs, including the lungs, prostate, and breast. These metastatic events correlate with a poorer prognosis, and treatments are predominantly palliative. Furthermore, traditional in-vivo models for bone …
de
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Christina Funk, Nadja Uhlig, Zsolt Ruzsics, Florentin Baur et autres
Viruses are able to efficiently penetrate cells, multiply and eventually kill infected cells, release tumor antigens and activate the immune system. Therefore, viruses are highly attractive novel agents for cancer therapy. Clinical trials with first generations of oncolytic viruses (OVs) are very …
de
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Matthias Peindl, Claudia Göttlich, Samantha A. W. Crouch, Niklas Hoff et autres
Epithelial-to-mesenchymal transition (EMT) is discussed to be centrally involved in invasion, stemness, and drug resistance. Experimental models to evaluate this process in its biological complexity are limited. To shed light on EMT impact and test drug response more reliably, we use a …
de
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Tanja Nadine Stüber, Razieh Monjezi, Lars Wallstabe, Johanna Kühnemundt et autres
Background Immunotherapy with chimeric antigen receptor (CAR)-engineered T-cells is effective in some hematologic tumors. In solid tumors, however, sustained antitumor responses after CAR T-cell therapy remain to be demonstrated both in the pre-clinical and clinical setting. A perceived barrier to the efficacy …
de
(code pays fourni par la source)
2020
article
OpenAlex
Maria Breun, Donato Daniel Martellotta, Anna Leberle, Sarah Nietzer et autres
de
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Florentin Baur, Sarah Nietzer, Meik Kunz, Fabian Saal et autres
To improve and focus preclinical testing, we combine tumor models based on a decellularized tissue matrix with bioinformatics to stratify tumors according to stage-specific mutations that are linked to central cancer pathways. We generated tissue models with BRAF-mutant colorectal cancer (CRC) cells …
de
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Nina Lodes, Katharina Seidensticker, Alexander Perniss, Sarah Nietzer et autres
Three-dimensional respiratory tissue models have been generated using, for example, human primary airway epithelial cells (hAEC) or respective cell lines. To investigate ciliopathies, such as primary ciliary dyskinesia, the presence of functional kinocilia in vitro is an essential prerequisite. Since access to …
de
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Lars Wallstabe, Claudia Göttlich, Lena C. Nelke, Johanna Kühnemundt et autres
Solid tumors impose immunologic and physical barriers to the efficacy of chimeric antigen receptor (CAR) T cell therapy that are not reflected in conventional preclinical testing against singularized tumor cells in 2-dimensional culture. Here, we established microphysiologic three-dimensional (3D) lung and breast …
de
(code pays fourni par la source)
2019
article
OpenAlex
Ezekiel R. Rozmus, Anika Langer, Elvira García de Jalón Viñegra, Gudrun Dandekar et autres
no, de
(code pays fourni par la source)
2019
article
OpenAlex
Michael M. Lübtow, Lena C. Nelke, Julia Seifert, Johanna Kühnemundt et autres
de, us
(code pays fourni par la source)
2019
article
OpenAlex
Meik Kunz, Julian Jeromin, Maximilian M. Fuchs, Jan Christoph et autres
Precision medicine has changed thinking in cancer therapy, highlighting a better understanding of the individual clinical interventions. But what role do the drivers and pathways identified from pan-cancer genome analysis play in the tumor? In this letter, we will highlight the importance …
de, it
(code pays fourni par la source)